News / Taiwan / economic_daily
Jinghua Biomedical Debuts on Taipei Exchange, Ramps Up Automation for Growth
Consumer Non-Durables · Food: Specialty/Candy · economic_daily · 2026-10-20
7806
Jinghua Biomedical has officially listed on the Taipei Exchange at NT$55 per share, focusing on expanding automated production lines to capture the growing demand for preventive healthcare products.
What Happened
Market Debut: Jinghua Biomedical has officially listed on the Taipei Exchange with an offering price of NT$55 per share. The company, founded in late 2019, specializes in traditional Chinese medicine extraction and is currently scaling up its production capacity through new automated facility projects.
Financial Performance: The company has demonstrated consistent revenue growth between 2024 and 2025. By leveraging a comprehensive database of over 1,000 customized formulas, Jinghua provides versatile product forms that cater to both brand clients and end-market consumers.
Technical Capabilities: Operating under a 'One-Stop CDMO' model, the company integrates traditional herbal wisdom with modern nutritional science. It holds key certifications such as ISO 22000 and HACCP, and is actively pursuing 'Health Food' certifications through rigorous efficacy and animal testing.
Strategic Outlook: Capitalizing on the post-pandemic surge in preventive medicine, the company is strengthening its presence in major e-commerce and TV shopping channels. Future growth is expected to be driven by continued patent development and the optimization of automated manufacturing processes to increase client loyalty.